TapImmune Recognizes National Breast Cancer Awareness Month With Renewed Urgency to Develop Cancer Vaccines

JACKSONVILLE, Florida, October 4, 2016 /PRNewswire/ --

TapImmune, Inc., (TPIV, TPIVD), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, is celebrating the month of October by reinforcing its efforts to prevent and cure breast and ovarian cancer.

In an open letter posted on the TapImmune website, the company's Chairman and CEO, Glynn Wilson, Ph. D, paid tribute to friends and loved one's who have been affected by cancer during National Breast Cancer Awareness Month.

Breast cancer is the most common cancer among women in the United States. Every two minutes a woman in the U.S. is diagnosed with breast cancer and approximately 40,500 are expected to die this year from the disease.

According to Wilson, over the past year there has been growing evidence that the approach of immuno-oncology, that stimulates the body's own immune system, will be a major force in the treatment of breast cancer.

TapImmune is making important progress in its development of T-cell vaccines for the treatment of breast and ovarian with the initiation of multiple Phase II clinical trials to determine the efficacy of its vaccines. The company's Phase II clinical trial in triple negative breast cancer is recruiting a total of 80 patients at eight different clinical centers in the U.S. and the first patients have already been treated.

"Immuno- therapy is now perceived in the medical community as the most promising treatment for cancer," said Glynn Wilson, Ph. D, Chairman and CEO, TapImmune. "We are proud to be at the forefront of immuno-oncology for breast cancer treatment and we are encouraged by our recent clinical progress. For us, we start National Breast Cancer Awareness Month in 2016 with renewed purpose towards our ultimate goal to save lives in indications that are in great need of new therapies."

To read Chairman Wilson's letter please CLICK HERE. For more details regarding the company's clinical development programs and recent news visit: http://www.tapimmune.com. For more inspiring stories about breast cancer survivors visit: http://breastcancermarathon.com/. Those interested in enrolling in a TapImmune sponsored clinical trial, please visit: https://clinicaltrials.gov/ct2/results?term=TapImmune&recr=Open.

About TapImmune Inc. 

TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company's website at http://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer 

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV 200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV 200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACT:
TapImmune Inc.
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

SOURCE TapImmune, Inc.